|
Gliomas
|
|
|
|
Timothy
F Cloughesy, John Kuhn, Patrick Wen, Susan M Chang, David Schiff, Harry
Greenberg, Larry Junck, Ian Robins, Lisa M DeAngelis, Al Yung, Morris Groves,
Karen Fink, Lauren E Abrey, Frank Lieberman, Minesh P Mehta, Jeff J Raizer, Ken
Hess, Michael Prados
Phase
II trial of R115777 (Zarnestra) in patients with recurrent glioma not taking
enzyme inducing antiepileptic drugs (EIAED): a North American Brain Tumor
Consortium (NABTC) report
38th
ASCO Annual Meeting. Orlando, FL. May 18-21, 2002.
Abstract No.
317
(Clinical Study)
|
|
Delmas
C, End D, Rochaix P, Favre G, Toulas C, Cohen-Jonathan E
The
Farnesyltransferase Inhibitor R115777 Reduces Hypoxia and Matrix
Metalloproteinase 2 Expression in Human Glioma Xenograft
Clin Cancer Res. 2003 Dec 1;9(16):6062-6068. (Animal Study, Abstract)
|
|
|
Glioblastoma |
|
|
|
|
Lustig R, Mikkelsen T, Lesser G, Grossman S, Ye
X, Desideri S, Fisher J, Wright For The Nabtt Cns Consortium J.
Phase II Pre-radiation R115777 (Zarnestra) in newly diagnosed GBM with
residual enhancing disease
Neuro Oncol. 2008 Aug 25; [Epub ahead of print]
 Abstract |
DBLinks |  BL 7:18
|
|
R. A. Lustig, T.
Mikkelesen, G. Lesser, S. Grossman, X.
Ye, S. Desideri, J. Fisher, J.
Wright New Approaches to Brain Tumor Therapy Consortium
Pre-radiation R115777 in patients with newly diagnosed glioblastoma
multiforme and residual enhancing disease
2005
ASCO Annual Meeting. Orlando, FL. May 13-17. Abstract No. 1518. (Clinical
Study)
Journal of Clinical Oncology, Vol 23, No 16S (June 1 Supplement), 2005:
1518
|
|
